Group 1 - The Shanghai Composite Index rose by 1.51% to close at 3883.56 points, while the Hang Seng Index increased by 1.94% to 25829.91 points [1] - Shanghai Pharmaceuticals Holding Co., Ltd. (referred to as "the company") has an AH premium of 66.35%, ranking 50th in AH stock premium rates [1] - The company's A-shares closed at 19.48 yuan, with a rise of 1.94%, and its H-shares closed at 12.79 Hong Kong dollars, increasing by 1.59% [1] Group 2 - The company is a large pharmaceutical group listed in both Shanghai and Hong Kong, with stock codes 02607 on the Hong Kong Stock Exchange and 601607 on the Shanghai Stock Exchange [1] - The company's main business covers pharmaceutical manufacturing and commerce, and it is included in the SSE 180 Index, CSI 300 Index, and MSCI China Index [1] - The company advocates core values of "innovation, integrity, cooperation, inclusiveness, and responsibility," aiming to enhance the quality of public health and become a respected leading brand in pharmaceutical manufacturing and health services [1] - The company is committed to innovation and has been increasing its investment in research and development to accelerate its transformation and development [1]

*注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 8月18日，上证指数涨0.85%，收报3728.03点，恒生指数跌0.37%，收报25176.85点。 上海医药AH溢价达62.94%，位居AH股溢价率第49位。当日收盘，上海医药A股报18.95元，涨幅 0.74%，H股报12.67港元，下跌0.39%。 资料显示，上海医药集团股份有限公司(以下简称"上海医药"或"公司")是沪港两地上市的大型医药产业 集团(港交所股票代码:02607;上交所股票代码:601607)。公司主营业务覆盖医药工业与商业,入选上证180 指数、沪深300指数成分股、摩根斯坦利中国指数(MSCI)。上海医药倡导"创新、诚信、合作、包容、 责任"的企业核心价值观,致力于持之以恒,提升民众的健康生活品质,努力打造成为受人尊敬、具有行业 美誉度的领先品牌药制造商和健康领域服务商。上海医药坚持创新发展,持续加大研发创新投入,加快创 新转型发展。 本文源自：金融界 作者：行情君 ...